Table 2.

Including neurosciences in psychiatric nosology

^*In 2011, Fibiger²² summarized the position of the pharmaceutical companies regarding psychopharmacological research. ^†The RDoC framework assumes that data from genetics and clinical neuroscience will yield biosignatures that will augment clinical symptoms and signs for clinical management. Examples where clinically relevant models of circuitry-behavior relationships augur future clinical use include fear/extinction, reward, executive function, and impulse control.²³